S. Cheesman

发表

Treatment of diffuse large B‐cell lymphoma with secondary central nervous system involvement: encouraging efficacy using CNS‐penetrating R‐IDARAM chemotherapy

K. Ardeshna, D. Linch, R. Joshi, 2016, British journal of haematology.

DT‐PACE/ESHAP chemotherapy regimens as salvage therapy for multiple myeloma prior to autologous stem cell transplantation

A. Mehta, C. Kyriakou, A. Wechalekar, 2020, British journal of haematology.

An alternative dosing strategy of lenalidomide for patients with relapsed multiple myeloma

Dean Smith, K. Yong, I. Khan, 2015, British journal of haematology.

Real world experience of bortezomib re‐treatment for patients with multiple myeloma at first relapse

K. Yong, N. Rabin, R. Popat, 2017, British journal of haematology.

Real‐world use of pomalidomide and dexamethasone in double refractory multiple myeloma suggests benefit in renal impairment and adverse genetics: a multi‐centre UK experience

R. Benjamin, M. Jenner, K. Ramasamy, 2017, British journal of haematology.

Atypical haemolytic uraemic syndrome in the eculizumab era: presentation, response to treatment and evaluation of an eculizumab withdrawal strategy

D. Gale, M. Scully, R. Shah, 2019, British journal of haematology.

Use of ixazomib, lenalidomide and dexamethasone in patients with relapsed amyloid light‐chain amyloidosis

P. Hawkins, C. Kyriakou, M. Fontana, 2020, British journal of haematology.

Hotel-based ambulatory care for complex cancer patients: a review of the University College London Hospital experience

K. Ardeshna, S. Morris, K. Peggs, 2012, Leukemia & lymphoma.

Introduction of Biosimilar Rituximab: A Hospital Perspective

S. Cheesman, 2020, HemaSphere.

Ixazomib with lenalidomide and dexamethasone for patients with relapsed multiple myeloma: impact of 17p deletion and sensitivity to proteasome inhibitors from a real world data-set

C. Kyriakou, A. Wechalekar, K. Yong, 2021, Leukemia & lymphoma.

REAL WORLD USE OF IXAZOMIB WITH LENALIDOMIDE AND DEXAMETHASONE FOR PATIENTS WITH RELAPSED AND RELAPSED REFRACTORY MULTIPLE MYELOMA

A. Mehta, C. Kyriakou, A. Wechalekar, 2017 .

Carfilzomib is an effective upfront treatment in AL amyloidosis patients with peripheral and autonomic neuropathy

P. Hawkins, C. Kyriakou, A. Wechalekar, 2019, British journal of haematology.

Rapid response to single agent daratumumab is associated with improved progression-free survival in relapsed/refractory AL amyloidosis

P. Hawkins, C. Kyriakou, C. Whelan, 2020, Amyloid : the international journal of experimental and clinical investigation : the official journal of the International Society of Amyloidosis.

Impact of timing of stem cell return following high dose melphalan in multiple myeloma patients with renal impairment: a single center experience

C. Kyriakou, S. Ings, A. Wechalekar, 2023, Leukemia & lymphoma.

Comparison of Rituximab originator (MabThera) to biosimilar (Truxima) in patients with immune‐mediated thrombotic thrombocytopenic purpura

M. Scully, J. Westwood, M. Thomas, 2019, British journal of haematology.